B+
Bull case
20%
Probability
Target price
$11.00
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
EPRX
EupraxiaDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
A positive placebo-controlled RESOLVE readout could materially improve confidence in EP-104GI. Company-reported EREFS, tissue-health, symptom, and tolerability signals provide an encouraging but preliminary setup, while the latest SEC-filed Q1 release supports near-term funding visibility.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -23.9.
What can break
Clinical development and regulatory timelines may slip or produce unfavorable outcomes.
Momentum
70
Value
41
Sentiment
39
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $6.50 · Bull $11.00 · Bear $3.40Analysis 2026-08-04; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $15.78
Why
Momentum70 · Δ7d +41.3
Value41 · Δ7d 0.0
Sentiment39 · Δ7d -23.9
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -23.9.
Contradictions & invalidation
- • Clinical development and regulatory timelines may slip or produce unfavorable outcomes.
- • Future financing may still be required; the company’s runway expectation includes potential warrant exercises and could involve dilution. [#SEC-6K-2026-05-12]
- • The open-label evidence is vulnerable to small-sample noise and may not translate into placebo-controlled efficacy.
Catalyst clock
2026-11-02
RESOLVE Phase 2b topline data expected in Q4 2026
Lead driver: Sentiment · See AI snapshot
Momentum
70
9% active weight
Current posture
7d trendImproving
Δ7d
+41.3
Δ21d
+33.3
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
39
62% active weight
Current posture
7d trendSoftening
Δ7d
-23.9
Δ21d
-18.4
Why this grade
Composite grade D. Momentum 70.4 / Value 41.2 / Sentiment 39.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-04. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$6.50
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$3.40
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$455.17M
Beta
1.50
Shares Out
65.91M
P/E (TTM) · Derived
-6.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-9.94
Rev YoY
-
EPS YoY
-12.8%
Gross Margin
-
Op Margin
-
Net Debt
-$80.41M
Current Ratio
16.00
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data